Patents by Inventor Yoko Murakami

Yoko Murakami has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10808006
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: October 20, 2020
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Publication number: 20190233466
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 1, 2019
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Patent number: 10208082
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Grant
    Filed: September 9, 2015
    Date of Patent: February 19, 2019
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Publication number: 20170260228
    Abstract: The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
    Type: Application
    Filed: September 9, 2015
    Publication date: September 14, 2017
    Applicant: Daiichi Sankyo Company, Limited
    Inventors: Yuji Kasuya, Yasuhiro Nakagami, Emiko Hatano, Tatsuya Inoue, Kazuhiro Yoshida, Satoshi Komoriya, Yoko Murakami, Masaru Iwasaki, Atsunobu Sakamoto, Kayoko Masuda, Masako Minami, Mayumi Iizuka, Yasunori Ono, Takashi Ohnuki
  • Publication number: 20120184747
    Abstract: This is to provide a novel aniline compound represented by the following formula (I) having an excellent broncho dilatory action based on potent EP2 agonistic action. A compound represented by the formula (I): or a salt thereof.
    Type: Application
    Filed: September 10, 2010
    Publication date: July 19, 2012
    Applicant: UBE INDUSTRIES, LTD.
    Inventors: Ryo Iwamura, Yoko Murakami, Masahiko Hagihara, Eiji Okanari
  • Patent number: D760111
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: June 28, 2016
    Assignee: MRK Fine Arts, LLC
    Inventors: Monica Rich Kosann, Rod G. Kosann, Yoko Murakami
  • Patent number: D760112
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: June 28, 2016
    Assignee: MRK Fine Arts, LLC
    Inventors: Monica Rich Kosann, Rod G. Kosann, Yoko Murakami
  • Patent number: D760620
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: July 5, 2016
    Assignee: MRK Fine Arts, LLC
    Inventors: Monica Rich Kosann, Rod G. Kosann, Yoko Murakami
  • Patent number: D787975
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: May 30, 2017
    Assignee: MRK Fine Arts, LLC
    Inventors: Monica Rich Kosann, Rod G. Kosann, Yoko Murakami
  • Patent number: D803091
    Type: Grant
    Filed: March 17, 2017
    Date of Patent: November 21, 2017
    Assignee: MRK Fine Arts, LLC
    Inventors: Monica Rich Kosann, Rod G. Kosann, Yoko Murakami